Management of unstable angina soon after myocardial infarction.
The recurrence of angina soon after myocardial infarction is not uncommon and represents areas of viable myocardium at risk from infarct extension and thus a worse prognosis. A better understanding of the pathogenesis of acute ischaemic syndromes and developments in interventional cardiology in the past decade have helped us rationalize our approach to this high-risk subset and achieve maximal myocardial salvage with its short- and long-term benefits.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000628:therapy*; D000789:Angina, Unstable / Q000503:physiopathology / Q000628:therapy*; D000800:Angioplasty, Balloon; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction; D009206:Myocardium / Q000378:metabolism; D009566:Nitrates / Q000627:therapeutic use; D010101:Oxygen Consumption; D011379:Prognosis
D000319:Adrenergic beta-Antagonists; D000925:Anticoagulants; D002121:Calcium Channel Blockers; D005343:Fibrinolytic Agents; D009566:Nitrates; D001241:Aspirin